Cargando…
Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens
The success of cancer immunotherapy relies on the induction of an immunoprotective response targeting tumor antigens (TAs) presented on MHC-I molecules. We demonstrated that the splicing inhibitor isoginkgetin and its water-soluble and non-toxic derivative IP2 act at the production stage of the pion...
Autores principales: | Darrigrand, Romain, Pierson, Alison, Rouillon, Marine, Renko, Dolor, Boulpicante, Mathilde, Bouyssié, David, Mouton-Barbosa, Emmanuelle, Marcoux, Julien, Garcia, Camille, Ghosh, Michael, Alami, Mouad, Apcher, Sébastien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921396/ https://www.ncbi.nlm.nih.gov/pubmed/33649389 http://dx.doi.org/10.1038/s42003-021-01801-2 |
Ejemplares similares
-
Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3
por: Boulpicante, Mathilde, et al.
Publicado: (2020) -
Exosome-driven transfer of tumor-associated Pioneer Translation Products (TA-PTPs) for the MHC class I cross-presentation pathway
por: Duvallet, Emilie, et al.
Publicado: (2016) -
The Biflavonoid Isoginkgetin Is a General Inhibitor of Pre-mRNA
Splicing
por: O'Brien, Kristine, et al.
Publicado: (2008) -
Molecular docking analysis of furfural and isoginkgetin with heme oxygenase I and PPARγ
por: Santhakumar, Preetha, et al.
Publicado: (2021) -
3′,8″-Dimerization Enhances the Antioxidant Capacity of Flavonoids: Evidence from Acacetin and Isoginkgetin
por: Li, Xican, et al.
Publicado: (2019)